Cell line · CVCL_1531
NCI-H2122
Cancer cell line, Homo sapiens. Lung adenocarcinoma. 54 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. NCI-H2122. Cell lines, record CVCL_1531. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1531
On this page
Cell line
As Cellosaurus gives it.
- Name
- NCI-H2122
- Accession
- CVCL_1531
- RRID
- RRID:CVCL_1531
- Synonyms
- H2122, H-2122, NCIH2122
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 46Y
- Category
- Cancer cell line
- Diseases
- Lung adenocarcinoma (NCIt C3512)
- Derived from
- Pleural effusion (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-08-14
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers54
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| NAPRT loss promotes lung tumor initiation and growth through AKT signaling independently of NAD+ biosynthesis. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of GABBR1 by New Ligand Valerate Transcriptionally Regulates ATF4-NRF2-CXCL13 Axis Mediating CD8+ T Cell Anti-Tumor Immunity. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD47 promotes mitogen-activated protein kinase and epithelial-to-mesenchymal transition molecular programs to drive prometastatic phenotypes in non-small cell lung cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual PD-1/IL-2Rα targeting restores CD8+ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 54
See all 54 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| From the same person | NCI-BL2122 | CVCL_2651 |
Source Cell lines
Cell banks4
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-5985 | ATCC | |
| AddexBio | C0016048/5013 | Cellosaurus | |
| CLS | 305600 | CLS | |
| KCLB | 92122 | KCLB |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1531
GET https://conductscience.org/api/cell-lines/v1/CVCL_1531/papers?page=2